Mammalian cell culture seed expansion patents: who holds the inoculum train claims
Filings are concentrated but not locked up. the top 5 assignees hold 24.6% of all 2,644 records in scope, and the top 10 hold 36.7% — leaving a long tail of single- and few-filing entrants. Filings peaked at 105 in 2018 and have declined since, falling from 79 in 2021 to 45 in 2024 — a 43% drop over that span. 2025 and 2026 figures are still filling in due to publication lag and should not be read as a continued slide.
- 1GENENTECH INC8.4%
- 2REGENERON PHARMACEUTICALS INC6.4%
- 3LIFE TECHNOLOGIES CORP3.8%
- 4TECHNION RES & DEV FOUND LTD3.3%
- 5AMGEN INC2.7%
See the full mammalian cell culture seed expansion analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
How many patents cover mammalian cell culture seed expansion?
This landscape identifies 2,644 published records filed against seeding density, passage number, viability threshold, doubling time, inoculum train and culture transition concepts within mammalian, animal and CHO cell culture, classified under C12N, C12M and C12Q. The count spans 2015 through the 2026-07-31 data cut-off. Because publication lags filing by roughly 18 months, the most recent one to two years are undercounted and will rise as those applications publish.
Who are the leading patent holders in mammalian cell culture seed expansion?
The ranked leaders include large biologics manufacturers and a university technology transfer office, with the top-ranked assignee holding 223 records against a fifth-place count of 71. The top 5 assignees combined account for 24.6% of all 2,644 records in scope, and the top 10 account for 36.7%. Most of the field's activity, however, sits with a long tail of assignees outside that ranked group.
Is filing activity in this field growing or declining?
Filing activity peaked at 105 records in 2018 and has since declined, falling from 79 in 2021 to 45 in 2024 — a 43% drop over that three-year span. 2024 is the most recent year in this dataset that can be treated as complete; 2025 and 2026 figures will increase as publications catch up. Treat any apparent drop in the very latest years as a lag artifact rather than a real trend.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Mammalian Cell Culture Seed Expansion covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.